Novartis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

27.07.15	GlobeNewswire/La Fondation Novartis confirme la nomination des nouveaux membres de son Conseil d'administration, y compris celle du nouveau Président, Joe... (Dow Jones)
27.07.15	GlobeNewswire/Novartis Stiftung bestätigt neue Mitglieder des Stiftungsrats und Dr. Jörg Reinhardt als neuen Vorsitzenden (Dow Jones)
24.07.15	Press Release: Novartis combination therapy -3- (Dow Jones)
24.07.15	Press Release: Novartis combination therapy -2- (Dow Jones)
24.07.15	Press Release: Novartis combination therapy Tafinlar(R) and Mekinist(R) achieves important EU and US regulatory milestones (Dow Jones)
16.07.15	Press Release: Novartis malaria treatment Coartem(R) 80/480mg receives WHO prequalification, enabling greater access for patients (Dow Jones)
07.07.15	Press Release: Novartis' new heart failure -2- (Dow Jones)
07.07.15	Press Release: Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure... (Dow Jones)
01.07.15	Press Release: Novartis: Alcon receives European -2- (Dow Jones)
01.07.15	Press Release: Novartis: Alcon receives European Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery (Dow Jones)
30.06.15	Press Release: Novartis Pharmaceuticals launches the first app for visually impaired people for use with the Apple Watch and other smart watches (Dow Jones)
29.06.15	Press Release: Novartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc. (Dow Jones)
29.06.15	Press Release: Novartis announces publication in -2- (Dow Jones)
29.06.15	Press Release: Novartis announces publication in The Lancet showing sustained efficacy with secukinumab over one year in psoriatic arthritis patients (Dow Jones)
26.06.15	Press Release: Novartis drug Farydak(R) -2- (Dow Jones)
26.06.15	Press Release: Novartis drug Farydak(R) recommended by CHMP for EU approval to treat multiple myeloma, providing patients a new mechanism of action (Dow Jones)
18.06.15	Press Release: Sandoz announces US launch of -2- (Dow Jones)
18.06.15	Press Release: Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone(R) 20mg (Dow Jones)
18.06.15	Press Release: Novartis highlights strong -3- (Dow Jones)
18.06.15	Press Release: Novartis highlights strong -2- (Dow Jones)
18.06.15	Press Release: Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day (Dow Jones)
16.06.15	Press Release: Novartis: Alcon receives European -2- (Dow Jones)
16.06.15	Press Release: Novartis: Alcon receives European approval for new trifocal presbyopia-correcting intraocular lens for patients undergoing cataract surgery (Dow Jones)
13.06.15	Press Release: Novartis presents new data from -2- (Dow Jones)
13.06.15	Press Release: Novartis presents new data from large European study reinforcing the benefit of first-line Tasigna(R) in newly-diagnosed patients with CML (Dow Jones)
13.06.15	Press Release: Novartis announces data show -2- (Dow Jones)
13.06.15	Press Release: Novartis announces data show majority of patients with polycythemia vera treated with Jakavi(R) achieved long-term disease control (Dow Jones)
12.06.15	Press Release: Novartis data at EHA show -2- (Dow Jones)
12.06.15	Press Release: Novartis data at EHA show increased PFS benefit of Farydak(R) in new subgroup of patients with previously treated multiple myeloma (Dow Jones)
12.06.15	Press Release: Novartis drug Arzerra(R) improved -2- (Dow Jones)
12.06.15	Press Release: Novartis drug Arzerra(R) improved median progression-free survival by 54% in patients with relapsed chronic lymphocytic leukemia (Dow Jones)
12.06.15	Press Release: Novartis reports new analysis -2- (Dow Jones)
12.06.15	Press Release: Novartis reports new analysis showing Xolair(R) improving quality of life by 78% for chronic spontaneous urticaria patients (Dow Jones)
11.06.15	Press Release: Novartis gains FDA approval for -3- (Dow Jones)
11.06.15	Press Release: Novartis gains FDA approval for -2- (Dow Jones)
11.06.15	Press Release: Novartis gains FDA approval for Promacta(R) providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder (Dow Jones)
11.06.15	Press Release: Novartis presents new data at WCD -2- (Dow Jones)
11.06.15	Press Release: Novartis presents new data at WCD demonstrating significant efficacy of Cosentyx(R) in patients with psoriasis of the nails, palms and soles (Dow Jones)
10.06.15	Press Release: Novartis announces new one-year -2- (Dow Jones)
10.06.15	Press Release: Novartis announces new one-year results demonstrating sustained secukinumab efficacy in ankylosing spondylitis patients (Dow Jones)
02.06.15	Press Release: Novartis presents new data at -2- (Dow Jones)
02.06.15	Press Release: Novartis presents new data at EULAR and WCD further demonstrating its leadership in severe long-term inflammatory and skin conditions (Dow Jones)
01.06.15	Press Release: Novartis highlights CTL019 data -2- (Dow Jones)
01.06.15	Press Release: Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma (Dow Jones)
01.06.15	Press Release: Novartis presents new data at ASCO -3- (Dow Jones)
01.06.15	Press Release: Novartis presents new data at ASCO -2- (Dow Jones)
01.06.15	Press Release: Novartis presents new data at ASCO for Zykadia(R) and combination of Tafinlar(R) and Mekinist(R) in certain NSCLC patients with unmet needs (Dow Jones)
31.05.15	Press Release: Combination of Novartis drugs -2- (Dow Jones)
31.05.15	Press Release: Combination of Novartis drugs Tafinlar(R) and Mekinist(R) shows significant survival benefit in patients with metastatic melanoma (Dow Jones)
27.05.15	Press Release: Novartis presents new data on 21 -2- (Dow Jones)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt

12.07.24

Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an

12.03.24

MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis

31.01.24

Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung

12.06.23

Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch

25.04.23

Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an

07.12.22

MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert